Charac, an NHS-integrated one-stop platform for independent community pharmacies, has secured £1 million strategic investment from the Royal Mail Group,
enabling its time-saving platform to assist more local pharmacies and patients across the UK to easily manage their prescriptions and consultations online.
The company said this new money will enable it to leverage strong levels of trust that pharmacists enjoy within the communities they serve in and will ensure
pharmacies remain a cornerstone of vibrant high streets and an invaluable provider of frontline healthcare products and services, including vitally needed
consultations.
Charac says it is aiming to sign up over 1,000 UK pharmacies in the next 12 months by expanding its geographic footprint beyond current cities, including London,
Manchester and Birmingham, and targeting small multiple and independent pharmacies, accounting for almost 40 per cent of the UK's community pharmacy network.
The announcement also sees the addition of Stefan Kulik, a managing director at Royal Mail, to the Charac board. Stefan is responsible for leading Royal Mail's
expansion into the healthcare industry and brings a breadth of experience, having previously worked in healthcare with companies including Johnson & Johnson.
The Royal Pharmaceutical Society (RPS) Assembly has announced the re-appointment of Professor Claire Anderson as President for a further term of two years on
Tuesday (11 July).
As president, Anderson will oversee delivery and implementation of the constitutional governance review; continue to extend the profile and influence of pharmacy
as a profession by building and strengthening relationships with all the other pharmacy leadership bodies and organisations.
She aims to ensure that RPS is invited to the table whenever medicines and public health are discussed by continuing to invest in strategic relationships beyond
pharmacy
Claire was first elected as President in 2021. In her address to the Assembly, Claire said: "This is a time of unprecedented change and I have decided to stand as
President for a second term to offer much needed continuity.
"I am passionate about our profession and committed to making the RPS and our members even more successful. I will also continue to be a dedicated ambassador and
advocate for the profession nationally and internationally."
Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges.
Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost
reduction.
The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their
network of logistics service providers.
This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising,
savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the
wider industry.
With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral
to achieving this.
The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.
Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director.
Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment
banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis.
For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research
Organisation.
In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry.
Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate
our position as a global leader in the Orphan Drug development market."